Sera Prognostics, Inc. appointed Scott Gleason as its new Chief Financial Officer and Treasurer, effective August 31, 2026. Gleason brings over 25 years of experience in healthcare finance and investor relations, having previously served as CFO at LarmorBio and NX Prenatal, and VP of Investor Relations at Neogen Corporation. Concurrently, outgoing CFO Austin Aerts stepped down from his executive role but will remain with the company as a consultant starting September 8, 2026, at a rate of $375 per hour for twelve months. The transition includes severance payments for Aerts totaling approximately $354,921 over nine months and an equity award valued at $500,000 for Gleason. Sera Prognostics operates in the health diagnostics industry, providing precision pregnancy care through its PreTRM test to predict preterm birth risk.

Sera Prognostics reported second quarter 2026 financial results with revenue of $30,000 compared to $17,000 in the prior year period. Total operating expenses were $10.0 million against $9.3 million previously, resulting in a net loss of $9.1 million versus an $8.0 million loss last year. The company ended the quarter with approximately $80.3 million in cash and securities. Key operational highlights include launching a fourth partnership program for its PreTRM test-guided care strategy, exceeding 2026 payer engagement objectives across more than 20 states, and Illinois enacting legislation mandating Medicaid coverage for preterm birth risk testing affecting approximately 50,000 annual births. Additionally, the company appointed Mark Capone to its Board of Directors and published PRIME study data demonstrating a 22% reduction in NICU admissions among first-time mothers. Sera Prognostics operates in the healthcare diagnostics industry, providing pregnancy biomarker tests to assess preterm birth risk.

On June 25, 2026, Sera Prognostics, Inc. appointed Mark Capone as a Class II director and member of the Compensation Committee, effective July 1, 2026. Mr. Capone's initial term expires at the 2029 annual meeting. On July 10, 2026, he will receive an initial equity award of the lesser of $167,072 in fair value (split between options and RSUs) or 150,000 option equivalents. He is also eligible for annual equity awards of the lesser of $88,359 or 75,000 option equivalents. Mr. Capone is a former CEO of Myriad Genetics and currently serves as CEO of Precision Medicine Advisors, LLC. The company operates in the healthcare industry and develops molecular diagnostics and precision medicine products.